Drug prices after Medicare negotiations may be a 'nothing burger' for Big Pharma
U.S. equity index futures green; Nasdaq 100 up ~1%
Euro STOXX 600 index up ~0.1%
Dollar, gold edge down; crude off ~1%; bitcoin edges up
U.S. 10-Year Treasury yield falls to ~3.86%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
DRUG PRICES AFTER MEDICARE NEGOTIATIONS MAY BE A 'NOTHING BURGER" FOR BIG PHARMA
Wall Street analysts and drugmakers appear at ease ahead of the U.S. government's release of the final prices of its first ever negotiation over prescription drugs as they expect the hit to sales to be less than originally feared.
BMO Capital analysts say the drug pricing release, expected in the next few days, could be "An August Nothing Burger for BioPharma in the Making".
"We expect the impacts of the IRA across the first round of negotiated drugs to be muted," said BMO analysts, referring to U.S. President Joe Biden's Inflation Reduction Act that includes the drug price provisions.
Four drugmakers - Bristol Myers Squibb, Johnson & Johnson, AbbVie, and AstraZeneca AZN.L - which have five of the 10 drugs chosen for the first wave of negotiations, had said last month they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs.
J.P.Morgan analysts say a "more manageable than feared Eliquis price cut in 2026" could start to bring Bristol Myers investors "back to the story".
Medicare is expected to announce cuts to list prices of at least 25% by Sept. 1, and the final prices will take effect in 2026.
Under President Joe Biden's Inflation Reduction Act (IRA), signed into law in 2022, the Medicare agency was required to identify the 100 most expensive drugs in the program and pick 10 for price negotiations that began last year.
(Mariam Sunny)
*****
FOR TUESDAY'S EARLIER LIVE MARKETS POSTS:
DOW INDUSTRIALS: 40K HURDLE STILL LOOMS LARGE - CLICK HERE
SHOCK HORROR: BRITISH WAGES ARE ACTUALLY RISING - CLICK HERE
WATCH RISING EUROPEAN GAS PRICES - CLICK HERE
EUROPEAN STOCKS: NEAR TERM DOWNSIDE, LONG TERM UPSIDE - BOFA SURVEY - CLICK HERE
CALM WATERS AS UTILITIES SUPPORT STOXX, TRAVEL DRAGS - CLICK HERE
HEALTHY START AHEAD FOR EUROPEAN STOCKS - CLICK HERE
STABLE YEN LEADS NIKKEI HIGHER AHEAD OF US DATA TEST - CLICK HERE
U.S. drugmakers part of Medicare drug price negotiation program https://tmsnrt.rs/4cns9t5
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
